China Shineway Pharmaceutical Group Limited
CSWYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,778 | $4,517 | $588 | $498 |
| % Growth | -16.4% | 668% | 18% | – |
| Cost of Goods Sold | $946 | $1,122 | $151 | $126 |
| Gross Profit | $2,832 | $3,394 | $437 | $373 |
| % Margin | 75% | 75.1% | 74.4% | 74.8% |
| R&D Expenses | $101 | $110 | $17 | $17 |
| G&A Expenses | $291 | $326 | $280 | $257 |
| SG&A Expenses | $1,889 | $2,308 | $2,098 | $1,756 |
| Sales & Mktg Exp. | $1,597 | $1,982 | $1,819 | $1,500 |
| Other Operating Expenses | $0 | $0 | $105 | $83 |
| Operating Expenses | $1,989 | $2,419 | $331 | $290 |
| Operating Income | $843 | $976 | $106 | $83 |
| % Margin | 22.3% | 21.6% | 18.1% | 16.6% |
| Other Income/Exp. Net | $303 | -$800 | $30 | $29 |
| Pre-Tax Income | $1,146 | $175 | $137 | $111 |
| Tax Expense | $306 | $38 | $29 | $25 |
| Net Income | $840 | $137 | $108 | $86 |
| % Margin | 22.2% | 3% | 18.3% | 17.3% |
| EPS | 1.11 | 0.18 | 0.14 | 0.11 |
| % Growth | 516.7% | 28.6% | 27.3% | – |
| EPS Diluted | 1.11 | 0.18 | 0.14 | 0.11 |
| Weighted Avg Shares Out | 755 | 755 | 755 | 755 |
| Weighted Avg Shares Out Dil | 755 | 755 | 755 | 755 |
| Supplemental Information | – | – | – | – |
| Interest Income | $177 | $95 | $14 | $15 |
| Interest Expense | $6 | $3 | $0 | $0 |
| Depreciation & Amortization | $69 | $9 | $9 | $10 |
| EBITDA | $1,221 | $1,252 | $145 | $121 |
| % Margin | 32.3% | 27.7% | 24.7% | 24.4% |